Tuberculosis remains one of the most consequential infectious disease challenges of the modern era, and a comprehensive new accounting of its toll forces a reckoning with how far the world still is from elimination targets — targets now further threatened by retreating global health investment. For health-conscious adults tracking population health trajectories, this analysis represents the most granular longitudinal picture of TB's reach yet assembled.
Drawing on the Global Burden of Disease Study 2023 framework, researchers modeled TB incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 through 2023. The analysis stratified outcomes by HIV co-infection status and drug-resistance profiles — including multidrug-resistant TB (MDR-TB) — using ensemble mortality modeling integrated with vital registration, surveillance, verbal autopsy, and minimally invasive tissue sampling data. Risk factor attribution was separately calculated for alcohol use, smoking, and elevated fasting plasma glucose, providing a behavioral lens on TB susceptibility alongside the biological. Progress benchmarks were evaluated against the WHO End TB Strategy's ambitious dual targets: a 95% reduction in TB deaths and a 90% reduction in incidence between 2015 and 2035.
This analysis arrives at a moment of particular urgency. MDR-TB represents a structurally different threat than drug-sensitive TB, requiring longer, more toxic, and significantly costlier treatment regimens — and its prevalence signals systemic failures in treatment adherence and healthcare infrastructure. The HIV-TB syndemic continues to disproportionately burden sub-Saharan Africa, where immunosuppression dramatically amplifies susceptibility and mortality. Critically, the convergence of MDR-TB expansion with documented reductions in global health funding creates a compounding risk scenario that the GBD data can now quantify with unprecedented geographic specificity. From an analytical standpoint, this is a landmark confirmatory and baseline-setting study rather than a paradigm-shifting mechanistic finding — but its epidemiological scope and policy relevance are substantial. Key limitations include the inherent uncertainty in verbal autopsy and surveillance-derived mortality estimates in low-registration settings, and the modeling assumptions embedded in DisMod-MR. Still, it provides an indispensable baseline for measuring the real-world cost of funding disruptions in the years ahead.